Targeting a diverse spectrum of cancers.
Kinase switch control inhibitors for tumor-targeted and immune-targeted cancer therapies.
Deciphera’s proprietary switch control platform has generated a diverse clinical pipeline of kinase inhibitor drug candidates including tumor-targeted therapies and immuno-targeted therapies.
12/07/18 4:00 PM EDT
© Nasdaq. Minimum 15 minutes delayed.
Deciphera Pharmaceuticals, Inc. to Present at the 30th Annual Piper Jaffray Healthcare Conference Read More »
Deciphera Pharmaceuticals Completes Enrollment in the INVICTUS Pivotal Phase 3 Clinical Study of DCC-2618 in Patients with Advanced Gastrointestinal Stromal Tumors Read More »
Deciphera Pharmaceuticals, Inc. Announces Third Quarter 2018 Financial Results Read More »